Dr. Francesca Micoli, Director GVGH Innovation Academy, GSK Vaccines Institute for Global Health, Italy
Dr. Francesca Micoli, born on October 5, 1977, in Martina Franca, Italy, is a renowned chemist and senior project leader at GSK Vaccines Institute for Global Health (Siena). With over two decades of experience in vaccine research and development, she currently directs the GVGH Innovation Academy, advancing solutions for bacterial diseases and working on cutting-edge vaccine technologies. Her expertise spans glycoconjugation, nanoparticle design, and mRNA stabilization.
Profile
Education 🎓
Francesca earned her Ph.D. in Chemistry from the University of Florence in 2006, specializing in industrial organic chemistry. Her academic foundation in organic synthesis and catalysis laid the groundwork for a prominent career in vaccine development and drug discovery.
Experience 🧪
Dr. Micoli’s career journey includes leading roles at GSK and Novartis, with a focus on vaccine chemistry, molecular biology, and immunoassay. She has managed teams, driven projects on vaccines for bacterial diseases, and pioneered innovative technology platforms. Her leadership at GVGH has been instrumental in progressing global vaccine programs from preclinical to clinical stages.
Research Interest 🔬
Francesca’s research interests lie in developing vaccines for bacterial infections, such as Shigella and Klebsiella, and advancing technology platforms like glycoconjugation, nanoparticles, and monoclonal antibodies. Her work contributes to combating global health threats and advancing immunization science.
Awards 🏆
Dr. Micoli is a Six-Sigma Black Belt and has received various professional recognitions. Her contributions to vaccine development and analytical chemistry are widely acknowledged, solidifying her position as a leader in the field.
Publication Top Notes 📚
Nappini et al. (2024). Modeling CDAP Chemistry to Design Glycoconjugate Vaccines. Vaccines (Basel). Link.
Monaci et al. (2024). 1H, 13C, and 15N assignment of MrkA Protein Antigen. Biomol NMR Assign. Link.
Leroux-Roels et al. (2024). Safety and Immunogenicity of GMMA-based Shigella Vaccine. J Infect Dis. Link.